JP2023506834A5 - - Google Patents

Info

Publication number
JP2023506834A5
JP2023506834A5 JP2022536639A JP2022536639A JP2023506834A5 JP 2023506834 A5 JP2023506834 A5 JP 2023506834A5 JP 2022536639 A JP2022536639 A JP 2022536639A JP 2022536639 A JP2022536639 A JP 2022536639A JP 2023506834 A5 JP2023506834 A5 JP 2023506834A5
Authority
JP
Japan
Prior art keywords
antigen
binding site
seq
amino acid
multispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022536639A
Other languages
English (en)
Japanese (ja)
Other versions
JP7734132B2 (ja
JP2023506834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064672 external-priority patent/WO2021119531A1/en
Publication of JP2023506834A publication Critical patent/JP2023506834A/ja
Publication of JP2023506834A5 publication Critical patent/JP2023506834A5/ja
Application granted granted Critical
Publication of JP7734132B2 publication Critical patent/JP7734132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022536639A 2019-12-11 2020-12-11 抗血清アルブミン抗体 Active JP7734132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946932P 2019-12-11 2019-12-11
US62/946,932 2019-12-11
PCT/US2020/064672 WO2021119531A1 (en) 2019-12-11 2020-12-11 Anti-serum albumin antibodies

Publications (3)

Publication Number Publication Date
JP2023506834A JP2023506834A (ja) 2023-02-20
JP2023506834A5 true JP2023506834A5 (cg-RX-API-DMAC7.html) 2023-12-18
JP7734132B2 JP7734132B2 (ja) 2025-09-04

Family

ID=76329090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536639A Active JP7734132B2 (ja) 2019-12-11 2020-12-11 抗血清アルブミン抗体

Country Status (8)

Country Link
US (1) US20230032087A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073114A4 (cg-RX-API-DMAC7.html)
JP (1) JP7734132B2 (cg-RX-API-DMAC7.html)
CN (1) CN115916816B (cg-RX-API-DMAC7.html)
AU (1) AU2020403153A1 (cg-RX-API-DMAC7.html)
CA (1) CA3161411A1 (cg-RX-API-DMAC7.html)
IL (1) IL293780A (cg-RX-API-DMAC7.html)
WO (1) WO2021119531A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
JP2025526875A (ja) * 2022-08-17 2025-08-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 改善された抗アルブミンナノボディおよびその使用
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025201474A1 (zh) * 2024-03-28 2025-10-02 诺纳生物(苏州)有限公司 血清白蛋白结合蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5185624B2 (ja) * 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
US8007796B2 (en) * 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MY167125A (en) * 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
EP3297672B1 (en) * 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3356405B1 (en) * 2015-10-02 2026-07-08 F. Hoffmann-La Roche AG Anti-human cd19 antibodies with high affinity
ES3056995T3 (en) * 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
CN113195544A (zh) * 2018-06-07 2021-07-30 库利南肿瘤股份有限公司 多特异性结合蛋白及其使用方法
CN119306844A (zh) * 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法

Similar Documents

Publication Publication Date Title
CN112955471B (zh) Cd3抗体及其药物用途
CN112969476B (zh) 多特异性蛋白分子
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2024522360A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
JP2024510098A5 (cg-RX-API-DMAC7.html)
CN111417653A (zh) Cd47抗原结合分子
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP7836033B2 (ja) Gprc5d抗体及びその応用
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2023506017A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2021512652A5 (cg-RX-API-DMAC7.html)
JP2024546763A5 (cg-RX-API-DMAC7.html)
CN117586412A (zh) 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2025511135A5 (cg-RX-API-DMAC7.html)
JP2025513714A5 (cg-RX-API-DMAC7.html)
IL277899B2 (en) Methods and preparations for treating yellow fever